Undisclosed lncRNA based cancer therapeutic / HAYA Therap - LARVOL DELTA

HAYA Therapeutics Awarded Innosuisse Certificate for Sustainable Growth and Funding to Advance Treatment for Aggressive Solid Tumors (Businesswire) - "HAYA Therapeutics...announced that it has been awarded the prestigious Innosuisse Certificate for Sustainable Growth from Innosuisse, the Swiss Innovation Agency, who also provided funding to support HAYA’s research into using its technology to address cancer. In addition to Innosuisse’s award for HAYA’s potential for growth and success, it is providing 1.5M CHF (approximately $1.64M USD) in non-dilutive funding for HAYA through Innosuisse’s Start-up Innovation Projects...The funds will be used over the next two years for translational studies to further develop an innovative therapy targeting cancer-associated fibroblast-specific lncRNA for aggressive solid tumors."

Financing • Solid Tumor